Consequently, tumors derived from DNAJA2-deficient cancer cells in animal models are highly responsive to the immune checkpoint blockade (ICB) therapy, which correlates with the ICB therapy result observed in cancer patients. The gene discussed is DNAJA2; the disease is cancer.